Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Haemonetics Corporation Common Stock (NY: HAE )

75.44 -1.46 (-1.90%)
Official Closing Price Updated: 7:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Haemonetics Corporation Common Stock

< Previous 1 2 3 4 5 Next >
While growth is established for NYSE:HAE, the stock's valuation remains reasonable.
For those who appreciate growth without the sticker shock, HAEMONETICS CORP/MASS (NYSE:HAE) is worth considering. 
Via Chartmill
This Constellation Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Via Benzinga
The Latest Analyst Ratings For Haemonetics
Via Benzinga
For those who appreciate growth without the sticker shock, NYSE:HAE is worth considering.
In the world of growth stocks, NYSE:HAE shines as a value proposition. 
Via Chartmill
Deep Dive Into Haemonetics Stock: Analyst Perspectives (7 Ratings)
Via Benzinga
NYSE:HAE is not too expensive for the growth it is showing.
While growth is established for NYSE:HAE, the stock's valuation remains reasonable. 
Via Chartmill
Despite its growth, NYSE:HAE remains within the realm of affordability.
HAEMONETICS CORP/MASS (NYSE:HAE), a growth stock which is not overvalued. 
Via Chartmill
What Analysts Are Saying About Haemonetics Stock
Via Benzinga
Investors should take note of NYSE:HAE, a growth stock that remains attractively priced.
Looking for growth without the hefty price tag? Consider NYSE:HAE. 
Via Chartmill
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
From Aligos Therapeutics
Via GlobeNewswire
NYSE:HAE stands out as a growth opportunity that won't break the bank.
Investors should take note ofHAEMONETICS CORP/MASS (NYSE:HAE), a growth stock that remains attractively priced. 
Via Chartmill
Analyst Expectations For Haemonetics's Future
Via Benzinga
Top 3 Health Care Stocks That Are Set To Fly This Quarter
Via Benzinga
Investors should take note of NYSE:HAE, a growth stock that remains attractively priced.
Investors seeking growth at a reasonable cost should explore HAEMONETICS CORP/MASS (NYSE:HAE). 
Via Chartmill
NYSE:HAE stands out as a growth opportunity that won't break the bank.
NYSE:HAE is not too expensive for the growth it is showing. 
Via Chartmill
Looking for growth without the hefty price tag? Consider NYSE:HAE.
HAEMONETICS CORP/MASS (NYSE:HAE) stands out as a growth opportunity that won't break the bank. 
Via Chartmill
NYSE:HAE, a growth stock which is not overvalued.
Despite its growth, HAEMONETICS CORP/MASS (NYSE:HAE) remains within the realm of affordability. 
Via Chartmill
Sotera Health Appoints Christopher Simon to the Board of Directors
From Sotera Health Services, LLC
Via GlobeNewswire
Haemonetics' Strategic Moves Poised To Boost Margins And Earnings, Says Analyst
Analyst upgrades Haemonetics to Buy, believes company can reach high-20% operating margin goal by FY26 through product mix analysis. Price target set at $112. 
Via Benzinga
This McCormick Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
Via Benzinga
These 3 Companies Boast Bright Outlooks
Favorable earnings estimate revisions are key for a stock to move higher. Let’s examine a few highly ranked stocks, including Stride, Interactive Brokers, and Haemonetics. 
Via Talk Markets
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
4 Analysts Assess Haemonetics: What You Need To Know
Via Benzinga
Earnings Scheduled For February 8, 2024
Companies Reporting Before The Bell • Ares Management (NYSE:ARES) is expected to report quarterly earnings at $1.09 per share on revenue of $864.54 million. 
Via Benzinga
HAE Stock Earnings: Haemonetics Beats EPS, Beats Revenue for Q4 2024
HAE stock results show that Haemonetics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2024. 
Via InvestorPlace
For those who appreciate growth without the sticker shock, NYSE:HAE is worth considering.
For those who appreciate growth without the sticker shock, NYSE:HAE is worth considering. 
Via Chartmill
Intuitive Surgical Stock Earns Relative Strength Rating Upgrade; Hits Key Benchmark
Intuitive Surgical stock saw a positive improvement to its Relative Strength (RS) Rating on Friday, with an increase from 74 to 85. 
Via Investor's Business Daily
Intuitive Surgical Stock Rating Climbs As Sales, Profits Rise
Intuitive Surgical stock got an IBD rating upgrade Monday. It edged up 0.37% to 274.16, its second day in a row of rising share price. 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Is HAEMONETICS CORP/MASS (NYSE:HAE) suited for quality investing?
Why the quality investor may take a look at HAEMONETICS CORP/MASS (NYSE:HAE). 
Via Chartmill
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.